Show simple item record

dc.contributor.authorSlattery, Meghanen_US
dc.contributor.authorBredella, Miriam Aen_US
dc.contributor.authorStanley, Takaraen_US
dc.contributor.authorTorriani, Martinen_US
dc.contributor.authorMisra, Madhusmitaen_US
dc.date.accessioned2014-12-02T21:29:02Z
dc.date.issued2014en_US
dc.identifier.citationSlattery, Meghan, Miriam A Bredella, Takara Stanley, Martin Torriani, and Madhusmita Misra. 2014. “Effects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girls.” International Journal of Pediatric Endocrinology 2014 (1): 22. doi:10.1186/1687-9856-2014-22. http://dx.doi.org/10.1186/1687-9856-2014-22.en
dc.identifier.issn1687-9848en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:13454811
dc.description.abstractBackground: Obesity is associated with a relative deficiency of growth hormone, which is predictive of greater visceral fat and markers of cardiovascular risk. The study’s purpose was to use recombinant human growth hormone (rhGH) as a physiologic probe to assess the effects of reversing obesity-related GH deficiency on body composition, cardiovascular risk markers, and insulin resistance. Methods: 22 obese girls 13–21 years old were followed for a randomized 6-month trial of rhGH vs. placebo/no treatment. At baseline and 6-months, DXA was performed for body composition, MRI to measure visceral, subcutaneous and total adipose tissue (VAT, SAT and TAT), and fasting blood drawn for IGF-1, inflammatory cardiovascular risk markers [soluble intercellular adhesion molecule (sICAM), high sensitivity CRP], lipids and HbA1C. An oral glucose tolerance test (OGTT) was performed. Twelve girls completed the 6-month visit. Baseline and mean 6-month change were compared between the groups using the Student t-test and the relationship between variables was determined through multiple regression analysis. Results: After 6-months, the rhGH group maintained IGF-1 levels, and had decreases in total cholesterol (p = 0.03), sICAM-1 (p = 0.04) and HbA1C (p = 0.03) compared to placebo/no treatment. The rhGH group trended towards greater decreases in LDL and 2-hour OGTT glucose. Glucose tolerance did not worsen with rhGH administration. Conclusions: Administering rhGH in small doses is able to stabilize IGF-1 levels in obesity. We have also shown that rhGH administration leads to an improvement in some markers of cardiovacular risk with without adversely affecting glucose tolerance. Trial registration Clinical Trial Registration Number: NCT01169103.en
dc.language.isoen_USen
dc.publisherBioMed Centralen
dc.relation.isversionofdoi:10.1186/1687-9856-2014-22en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247194/pdf/en
dash.licenseLAAen_US
dc.subjectAdolescentsen
dc.subjectGrowth hormoneen
dc.subjectVisceral faten
dc.subjectBody compositionen
dc.subjectFemalesen
dc.subjectInflammatory markersen
dc.titleEffects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girlsen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalInternational Journal of Pediatric Endocrinologyen
dash.depositing.authorBredella, Miriam Aen_US
dc.date.available2014-12-02T21:29:02Z
dc.identifier.doi10.1186/1687-9856-2014-22*
dash.contributor.affiliatedTorriani, Martin
dash.contributor.affiliatedStanley, Takara
dash.contributor.affiliatedMisra, Madhusmita
dash.contributor.affiliatedBredella, Miriam


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record